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ABSTRACT
Objective:The purpose ofthis study was to compare erythromycin and azithromycin in the treatment
of chlamydial cervicitis during pregnancy with regard to efficacy, side effects, and compliance.
Metkods: In a prospective manner, 48 pregnant patients with cervical chlamydial infections
diagnosed by routine screening tests were randomly assigned to receive either erythromycin, 500
mg q.i.d, for 7 days (N 24), or azithromycin, 1 g as a one-time dose (N 24). All sexual partners
were given prescriptions for doxycycline, 100 mg b.i.d, for 7 days. The treatment efficacy was
assessed by follow-up chlamydia testing 3 weeks after the therapy was completed. The side effects,
intolerance to therapy, and overall compliance were evaluated by means of a standardized post-
treatment questionnaire.
Results: There was no significant difference in cure rates noted between the erythromycin group
and the azithromycin group (77% vs. 91%, respectively; P- 0.24). Gastrointestinal side effects
were reported more frequently among patients treated with erythromycin compared with patients
treated with azithromycin (45% vs. 17%, respectively; P 0.004). The patients who received eryth-
romycin reported intolerance to therapy secondary to side effects more frequently than patients
who received azithromycin (23% vs. 4%, respectively; P 0.07). Furthermore, the patients in the
azithromycin group were more likely to complete their course of therapy as prescribed than the
patients in the erythromycin group (100% vs. 61%, respectively; P 0.002).
Conclusions:Azithromycin is efficacious and well tolerated for the treatment ofchlamydial cervici-
tis in pregnancy. Erythromycin, though efficacious, is poorly tolerated, as demonstrated by the
number of patients reporting significant side effects during the course of therapy. Since the cost of
azithromycin is comparable to that of generic erythromycin, the present study supports the use
of azithromycin as an alternative to erythromycin for the treatment of chlamydial cervicitis in
pregnancy. (C) 1996 Wiley-Liss, Inc.
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h/amydia trachomatis is the most common sexu-
ally transmitted bacterial infection in the
United States. The reported prevalence of this in-
fection among pregnant women ranges from 5% to
26%, depending on the population studied. Chla-
mydial infections have been associated in some
studies with adverse perinatal outcomes such as low
birth weight because of preterm rupture of the
membranes and subsequent preterm delivery.
3-6
Neonatal infection is manifested by clinical con-
junctivitis in 20-35% and neonatal pneumonia in
10-20% of infants born to mothers with untreated
chlamydial cervicitis. 7’8 The diagnosis and treat-
ment of chlamydia-infected women before delivery
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have been shown to significantly lower the risk of
these perinatal and neonatal complications.
9-11
The current first-line treatment for chlamydial
infection in pregnant women as recommended by
the Centers for Disease Control and Prevention
(CDC) is erythromycin base, 500 mg q.i.d, for 7
days. *z Erythromycin, however, is commonly associ-
ated with gastrointestinal side effects which often
prevent patients from completing the prescribed
course of therapy. Consequently, the failure rate of
erythromycin in pregnantwomen has been reported
to be as high as 15%. Alternative antibiotics, such
as amoxicillin, have been shown to be equally ef-
fective as erythromycin but better tolerated. 13’14
Azithromycin, which has been shown to be as effec-
tive as standard therapy for the treatment of chla-
mydia in nonpregnant patients, has the advantage
of being a one-time dose regimen. 15’6
This randomized trial was conducted to evaluate
the efficacy of azithromycin as an alternative to
erythromycin for the treatment of chlamydial infec-
tions during pregnancy. We also sought to compare
the rates of side effects and compliance of the 2
regimens.
SUBJECTS AND METHODS
All pregnant women registering for care at Thomas
Jefferson University Hospital’s prenatal clinic un-
dergo cervical chlamydia screening at their first pre-
natal visit. From August 1994 through April 1995, all
prenatal patients with positive cervical chlamydia
screening tests were offered enrollment in this
study. The exclusion criteria included first prenatal
visit at ->36 weeks, antibiotic use for any indication
within 14 days of enrollment, diagnosed coinfection
with Neisseria gonorrhoeae, and known allergy or sen-
sitivity to either of the study medications.
All cervical specimens were obtained from the
endocervical canal, after the ectocervix was cleared
of secretions, with a Dacron-tipped swab. The spec-
imens were transported to the virology laboratory
for analysis with a commerically available test kit
for detection of chlamydia-specific DNA sequences
using polymerase chain reaction (PCR) amplifica-
tion (Amplicor STD Specimen Collection and
Transport Kit, Roche Diagnostic Systems, Nutley,
NJ). The swabs were transported and stored in Am-
plicorTM specimen transport media until processing;
all specimens not evaluated within 24 h ofcollection
were stored in a -75C freezer until analysis. We
have previously demonstrated this assay to have a
sensitivity for chlamydia detection that is superior
to standard McCoy cell culture (97% vs. 88%). 17 In
this study, the samples that were positive by PCR
but negative by culture were subsequently culture-
positive with repeat testing or spin-down proce-
dures. In addition, the positive predictive values of
the 2 testing techniques were found to be equiva-
lent (98% for PCR and 100% for culture).
Each eligible patient gave written informed con-
sent in accordance with a protocol approved by the
University’s Institutional Review Board. They were
randomly assigned to of 2 treatment groups: eryth-
romycin base, 500 mg orally, q.i.d, for 7 days, or
azithromycin, g orally as a one-time dose. The
patients in both groups were supplied with medica-
tion at the time ofenrollment. Their sexual partners
were all given prescriptions for doxycycline, 100 mg
orally b.i.d, for 7 days. The patients were instructed
to abstain from sexual intercourse until after their
follow-up appointment.
The treatment group assignment was deter-
mined through block-of-six randomization gener-
ated from a random-number table. The treatment
regimens were placed within sequentially num-
bered, sealed opaque envelopes, with the clinic staff
involved in patient enrollment unaware of the ran-
domization block size.
All patients were scheduled for follow-up ap-
pointments for retesting 3 weeks after completing
their assigned therapy. They were instructed to re-
port if they or their sexual partners were unable to
complete the prescribed course of antibiotics and
to record the reason for their noncompliance. Com-
pliance was defined as a completion of the course
of therapy as prescribed. Each patient was given
a 1-page side effect questionnaire at the time of
enrollment which was collected during their return
visit for a follow-up test-of-cure.
Normally distributed continuous variables were
compared between the groups by means of an un-
paired Student’s t-test. Ordinal measurements as
well as non-normally distributed continuous vari-
ables were compared with Wilcoxon’s rank sum
test. P < 0.05 was considered significant. All re-
ported comparisons were 2-tailed.
RESULTS
A total of 48 eligible patients were enrolled in the
study and randomized to of the 2 treatment arms.
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TABLE I. Patient demographics
Erythromycin Azithromycin P
Mean age (years) 19.8 __+ 3.3 21.3 ___
4.0 0.17
Mean weight (Ib) 155 29 162 30 >0.5
Mean gestational age at 19.5 +__ 4.5 19.3 +_ 3.5 >0.5
enrollment (weeks)
TABLE 2. Cure rate, side effects, and compliance
% %
Azithromycin Erythromycin
Cure rate 91 77 0.24
Side effects (all 17 45 0.004
gastrointestinal)
Intolerance to therapy 4 23 0.07
Compliance 100 61 0.002
Only patient declined entry. She was treated with
erythromycin, but not included in this analysis.
The demographic characteristics of the patients
in each treatment group are shown in Table 1.
There were no statistically significant differences
in age, parity, weight, or gestational age at the time
of enrollment between the 2 groups.
Of the 48 patients, 24 received azithromycin and
24 received erythromycin. Three patients were lost
to follow-up, 1 in the azithromycin group and 2 in
the erythromycin group. The overall cure rates were
91% for the azithromycin group and 77% for the
erythromycin group (Table 2). This difference was
not statistically significant.
The treatment groups were compared with re-
gard to side effects, intolerance to therapy, and over-
all compliance (Table 2). Gastrointestinal side ef-
fects were reported by 17% of patients in the
azithromycin group compared with 45% of the pa-
tients in the erythromycin group (P 0.004). Intol-
erance to therapy due to severe gastrointestinal side
effects was reported by 4% of the patients in the
azithromycin group compared with 23% of the pa-
tients in the erythromycin group (P 0.07). Three
patients in the erythromycin group did not take the
medication as prescribed, although their noncom-
pliance was unrelated to side effects. These pa-
tients acknowledged not always remembering to
take their medication at appropriately close inter-
vals and therefore skipped several doses. Conse-
quently, the overall compliance was noted to be
100% in the azithromycin group compared with 61%
in the erythromycin group (P 0.002).
DISCUSSION
The current standard therapy for a pregnant woman
with a cervical chlamydial infection is erythromycin
base, 500 mg q.i.d, for 7 days. lz Because of the
high rate of gastrointestinal side effects with this
treatment, many patients are unable to complete
the prescribed course of therapy. This decrease in
patient compliance results in a decrease in efficacy
and a concomitantly lower impact on the prevention
of both perinatal and neonatal effects of untreated
maternal chlamydial infections.
Several studies have evaluated alternative treat-
ment regimens for antepartum chlamydia using
medications that are equally effective but better
tolerated than erythromycin. Amoxicillin has been
shown to be equally efficacious to erythromycin
in the treatment of chlamydia in pregnancy, with
significantly lower rates of side effects. 13’4 Still,
amoxicillin requires treatment over an extended
time which may result in noncompliance. It has
been demonstrated, in fact, that the level ofcompli-
ance with prescribed therapies deteriorates with
longer courses of tablet taking.
8
Azithromycin is the prototype of a new group of
antibiotics known as the azalides. It is chemically
related to erythromycin, but differs in its microbio-
logic spectrum, tolerability, and unique pharmaco-
kinetics. It is avidly taken up by cells, resulting in
high and sustained concentrations in tissues. This
unique pharmacokinetic profile allows it to be effec-
tive when administered as a one-time dose.
In vitro studies have shown that azithromycin
has excellent activity against clinical isolates of C.
trachomatis.9 Clinical experience with azithromycin
in non-pregnant patients has shown it to be as effec-
tive as "standard" therapy for the treatment of chla-
mydial cervicitis. 5,16 It is FDA approved as a class
B medication for use during pregnancy. However,
limited experience exists with regard to the efficacy
of a single-dose drug such as azithromycin in preg-
nant patients, who exhibit drug metabolism and
plasma volumes of distribution quite different from
nonpregnant women. The cost of azithromycin tab-
lets is roughly twice that of generic erythromycin.
The new azithromycin powder preparation, how-
ever, is comparable in cost with generic eryth-
romycin.
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Only series has been published to date compar-
ing azithromycin with erythromycin for the treat-
ment of chlamydial infections in pregnant women.
In a randomized study, Bush and Rosa reported a
100% cure rate for azithromycin compared with a
93% cure rate for erythromycin, with significantly
fewer side effects among the patients receiving
azithromycin. This study, however, had a sample
size of 30 patients which limited its ability to detect
a meaningful difference in treatment effect.
The results of our study suggest that azithro-
rnycin is as efficacious as erythromycin for the treat-
ment of chlamydial infections in pregnancy. It is
true that the possibility of a 13 or type II error in
our study exists in view ofthe small sample size. For
example, in order to detect a difference in treatment
effect between the groups of 50% (assuming an ot
error 0.05, a 13 error 0.2, and baseline failure
rate in the control group of 10%), we estimated that
approximately 472 patients would be required in
each group. Therefore, our results provide prelimi-
nary evidence that azithromycin may be a reason-
able efficacious alternative treatment for infection
with C. trachomatis during pregnancy.
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